Cost-effectiveness analysis of adding a quadrivalent HPV vaccine to the cervical cancer screening programme in Switzerland

References

• EKIF. Directive and recommendation no. 21: HPV vaccination recommendation. July 2007
   Google Scholar
• Schiffman M, Castle PE, Jeronimo J, et al. Human papillomavirus and cervical cancer. Lancet 2007;370:890–907
   PubMed Web of Science ®Google Scholar
• Koutsky L. Epidemiology of genital human papillomavirus infection. Am J Med 1997;102:3–8
   PubMedGoogle Scholar
• Insinga RP, Dasbach EJ, Elbasha EH. Assessing the annual economic burden of preventing and treating anogenital human papillomavirus-related disease in the US: analytic framework and review of the literature. Pharmacoeconomics 2005;23:1107–22
   Google Scholar
• Persson G, Dahlof LG, Krantz I. Physical and psychological effects of anogenital warts on female patients. Sex Transm Dis 1993;20:10–3
   Google Scholar
• Maw RD, Reitano M, Roy M. An international survey of patients with genital warts: perceptions regarding treatment and impact on lifestyle. Int J STD AIDS 1998;9:571–8
   Google Scholar
• Clifford GM, Smith JS, Plummer M, et al. Human papillomavirus types in invasive cervical cancer worldwide: a meta-analysis. Br J Cancer 2003;88:63–73
   PubMed Web of Science ®Google Scholar
• Clifford GM, Smith JS, Aguado T, et al. Comparison of HPV type distribution in high-grade cervical lesions and cervical cancer: a meta-analysis. Br J Cancer 2003;89:101–5
   PubMed Web of Science ®Google Scholar
• Von Krogh G. Management of anogenital warts (condylomata acuminata). Eur J Dermatol 2001;11:598–603
   PubMed Web of Science ®Google Scholar
• Clifford GM, Rana RK, Franceschi S, et al. Human papillomavirus genotype distribution in low-grade cervical lesions: comparison by geographic region and with cervical cancer. Cancer Epidemiol Biomarkers Prev 2005;14:1157–64
   PubMed Web of Science ®Google Scholar
• Anttila A, Ronco G, Clifford G, et al. Cervical cancer screening programmes and policies in 18 European countries. Br J Cancer 2004;91:935–41
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. New Engl J Med 2007;356:1928–43
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against Human Papillomavirus to prevent high-grade cervical lesions. New Engl J Med 2007;356:1915–27
   PubMed Web of Science ®Google Scholar
• Myers ER, McCrory DC, Nanda K, et al. Mathematical model for the natural history of human papillomavirus infection and cervical carcinogenesis. Am J Epidemiol 2000;151:1158–71
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Myers ER. Potential health and economic impact of adding a human papillomavirus vaccine to screening programs. J Am Med Assoc 2003;290:781–9
   PubMed Web of Science ®Google Scholar
• Kulasingam SL, Bénard S, Barnabas RV, et al. Adding a quadrivalent human papillomavirus vaccine to the UK cervical cancer screening programme: a cost-effectiveness analysis. R Cost Eff Resour Alloc [in press]
   Google Scholar
• www.ofs.ch [last accessed 28 November 2007]
   Google Scholar
• Kim JJ, Wright TC, Goldie SJ. Cost-effectiveness of human papillomavirus DNA testing in the United Kingdom, The Netherlands, France, and Italy. J Natl Cancer Inst 2005;97:888–95
   Google Scholar
• Pierre Pury. Cancer in Switzerland – statistics of incidence 1985–2003. Association of Swiss Cancer Registries – June 2006 (vol 1 and 2)
   Google Scholar
• Martin X. L’hystérectomie élargie laparoscopico-vaginale dans le traitement des cancers du col utérin 1997, Thèse
   Google Scholar
• Lamblin G. Association radio-chirurgicale dans le traitement du cancer du col utérin de plus de 4 cm 2001, Thèse
   Google Scholar
• Siebert U, Muth C, Sroczynski G, et al. Dünnschichtpräparationen und computergestützte Untersuchungen von Zervixabstrichen im Rahmen der Krebsfrüherkennung – Medizinische Effektivität, gesundheitsökonomische Evaluation und systematische Entscheidungsanalyse [Liquid-based preparation and computer- assisted examination of cervical smears. Clinical effectiveness, economic evaluation, and systematic decision analysis]. Health Technology Assessment, vol 35 (Series of the German Institute for Medical Documentation and Information commissioned by the Federal Ministry of Health and Social Security). St. Augustin: Asgard; 2003. [444 pages]
   Google Scholar
• http://www.who.int [last accessed 28 November 2007]
   Google Scholar
• Monsonego J, Breugelmans G, Bouée S, et al. Anogenital warts incidence, medical management and costs in women consulting gynaecologists in France]. Gynecol Obstet Fertil 2007;35:107–13
   Google Scholar
• Gieseking F, Petry KU, Hillemanns P, et al. Incidence, prevalence and costs of treating genital warts in the pre- HPV vaccine era in Germany. Florence: International Society for Pharmacoeconomics and Outcomes Research (ISPOR); November 2005
   Google Scholar
• Balthasar H, Spencer B, Addor V. Indicateurs de santé sexuelle et reproductive en Suisse – Monitorage. Swiss Health Observatory 2004
   Google Scholar
• Olsson SE, Villa LL, Costa RLR, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine 2007;25:4931–9
   PubMed Web of Science ®Google Scholar
• Gerber S. Screening management and costs in the CHUV of Lausanne over a 5 year period. 2007. [Personal communication]
   Google Scholar
• Gerber S, Heinzl S. Management of HPV related diseases in Switzerland. 2007. [Personal communication]
   Google Scholar
• http://www.tarmed.ch/f.las [last accessed 28 November 2007]
   Google Scholar
• http://www.kompendium.ch/ [last accessed 28 November 2007]
   Google Scholar
• Arveux P, Bénard S, Bouée S, et al. Invasive cervical cancer treatment costs in France. Bull Cancer 2007;94:219–24
   PubMed Web of Science ®Google Scholar
• Petry KU, Breugelmans JG, Bénard S, et al. Cost of screening and treatment of cervical dyskaryosis in Germany. Eur J Gynaecol Oncol [in press]
   Google Scholar
• Brown RE, Breugelmans JG, Theodoratou D, et al. Costs of detection and treatment of cervical cancer, cervical dysplasia and genital warts in the UK. Curr Med Res Opin 2006;22:663–70
   PubMed Web of Science ®Google Scholar
• Elbasha EH, Dasbach EJ, Insinga RP. Model for assessing human papillomavirus vaccination strategies. Emerg Infect Dis 2007;13:28–41
   PubMed Web of Science ®Google Scholar
• Bergeron C, Largeron N, McAllister R, et al. Cost-effectiveness analysis of the introduction of a quadrivalent Human Papillomavirus vaccine in France. Int J Technol Assess Health Care 2008;24:10–9
   PubMed Web of Science ®Google Scholar
• Ess SM, Schaad UB, Gervaix A, et al. Cost-effectiveness of a pneumococcal conjugate immunisation program for infants in Switzerland. Vaccine 2003;21:3273–81
   PubMed Web of Science ®Google Scholar
• Ruedin HJ, Ess S, Zimmermann HP, et al. Invasive meningococcal and pneumococcal disease in Switzerland: cost-utility analysis of different vaccine strategies. Vaccine 2003;21:4145–52
   PubMed Web of Science ®Google Scholar
• Brisson M, Van de Velde N, De Wals P, et al. The potential costeffectiveness of prophylactic human papillomavirus vaccines in Canada. Vaccine 2007;25:5399–408
   PubMed Web of Science ®Google Scholar
• De Vries R, Van Bergen JAEM, de Jong-van den Berg LTW, et al. Cost-utility of repeated screening for Chlamydia trachomatis. Value in Health 2007;9:1–11
   Google Scholar
• National Institute for Clinical Excellence. Guide to the methods of technology appraisal. 2004. [Reference NO515]
   Google Scholar
• Neilson A, Freisleben de Blasio B. Økonomisk evaluering av humant papillomavirus (HPV) vaksinasjon i Norge. Oslo: Nasjonalt kunnskapssenter for helsetjenesten (NOKC); 2007. [Nr 12–2007]
   Google Scholar
• National Board of Health, Danish Centre for Health Technology Assessment. Reduction in the risk of cervical cancer by vaccination against human papillomavirus (HPV) – a health technology assessment. Copenhagen: National Board of Health, Danish Centre for Health Technology Assessment, 2007. Series Name: Danish Centre for Health Technology Assessment 2007; 2007 9(1)
   Google Scholar
• Thiry N, Lambert M-L, Cleemput I, et al. Vaccination HPV pour la prévention du cancer du col de l’utérus en Belgique: Health Technology Assessment. Health Technology Assessment (HTA). Bruxelles: Centre federal d’expertise des soins de santé (KCE); 2007. KCE reports 64B (D2007/10.273/42)
   Google Scholar
• Bergeron C, Breugelmans JG, Bouée S, et al. Cervical cancer screening and associated treatment costs in France. Gynecol Obstet Fertil 2006;34:1036–42
   Google Scholar
• Dasbach E, Insinga R, Elbasha E. Assessment of the health and economic impact of a quadrivalent HPV vaccine in the United Kingdom using a transmission dynamic model [abstract]. European Research Organization on Genital Infection and Neoplasia (EUROGIN), Monaco, October 4–6, 2007
   Google Scholar
• Van de Velde N, Brisson M, Boily MC. Modeling human papillomavirus vaccine effectiveness: quantifying the impact of parameter uncertainty. Am J Epidemiol 2007;165:762–75
   PubMed Web of Science ®Google Scholar
• Newall AT, Beutels P, Good JG, et al. Cost-effectiveness analyses of human papillomavirus vaccination. Lancet Infect Dis 2007;7:289–96
   PubMed Web of Science ®Google Scholar
• Guidance of the introduction of HPV vaccines in EU countries. 2008: http://ecdc.europa.eu/ [last accessed 14 February 2008]
   Google Scholar
• Jakobsson M, Gissler M, Sainio S, et al. Preterm delivery after surgical treatment for cervical intraepithelial neoplasia. Obstet Gynecol 2007;109:309–13
   PubMed Web of Science ®Google Scholar
• Russell RB, Green NS, Steiner CA, et al. Cost of hospitalization for preterm and low birth weight infants in the United States. Pediatrics 2007;120:e1–e9
   PubMed Web of Science ®Google Scholar
• Brown D. HPV Type 6/11/16/18 vaccine: first analysis of crossprotection against persistent infection, cervical intraepithelial neoplasia (CIN), and adenocarcinoma in situ (AIS) caused by oncogenic HPV types in addition to 16/18 [abstract G-1720b]. 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, USA, September17–20, 2007
   Google Scholar
• Canfell K, Barnabas R, Patnick J, et al. The predicted effect of changes in cervical screening practice in the UK: results from a modelling study. Br J Cancer 2004;91:530–6
   PubMed Web of Science ®Google Scholar
• Bigras G, de Marval F. The probability for a Pap test to be abnormal is directly proportional to HPV viral load: results from a Swiss study comparing HPV testing and liquid-based cytology to detect cervical cancer precursors in 13 842 women. Br J Cancer 2005;93:575–81
   PubMed Web of Science ®Google Scholar
• Nanda K, McCrory DC, Myers ER, et al. Accuracy of the Papanicolaou test in screening for and follow-up of cervical cytologic abnormalities: a systematic review. Ann Intern Med 2000;132:810–9
   PubMed Web of Science ®Google Scholar
• Arbyn M, Buntinx F, Van Ranst M, et al. Virologic versus cytologic triage of women with equivocal Pap smears: a metaanalysis of the accuracy to detect high-grade intraepithelial neoplasia. J Natl Cancer Inst 2004;96:280–93
   PubMed Web of Science ®Google Scholar
• Mitchell MF, Schottenfeld D, Tortolero-Luna G, et al. Colposcopy for the diagnosis of squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol 1998;91:626–31
   Google Scholar
• Karnon J, Peters J, Platt J, et al. Liquid-based cytology in cervical screening: an updated rapid and systematic review and economic analysis. Health Technol Assess 2004;8:iii, 1–78
   Google Scholar